Adverse cardiovascular drug interactions.
Opie
L H
LH
Heart Research Unit, University of Cape Town, South Africa.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000075202:Contraindications; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000009:adverse effects / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D005343:Fibrinolytic Agents; D014665:Vasodilator Agents; D006903:Hydroxymethylglutaryl CoA Reductases